ALK and non-small cell lung carcinoma: Patients with NSCLC without driver mutations (EGFR or ALK), with any PD-L1 TC or IC level and ineligible to platinum-based chemotherapy due to poor PS (ECOG ≥ 2) or to age (≥70 years), were randomized 2:1 to Atezolizumab every 3 weeks or single-agent chemotherapy Vinorelbine (oral or intravenous) or Gemcitabine.